Promising lymphoma combo trial pulled before it even started
NCT ID NCT06767956
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test a combination of two drugs—golcadomide and nivolumab—in people with non-Hodgkin lymphoma whose cancer did not respond or came back after CAR-T cell therapy. The goal was to find a safe dose and see if the combo could shrink tumors. However, the trial was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Golcadomide and nivolumab
- What this could lead to
- If it had worked, this could have pointed toward a new treatment option for patients whose lymphoma returns after CAR-T therapy.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no results are available. The combination may have had safety or efficacy issues that stopped the study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells be engineered to fight blood cancer?